{"entity":{"id":"nct04969887","kind":"trial","name":"Combination Immunotherapy in Rare Cancers Under InvesTigation","aka":["MOST-CIRCUIT"],"tldr":"A phase 2 trial of nivolumab and ipilimumab in gallbladder cancer and other biliary tract cancers, run by Olivia Newton-John Cancer Research Institute, active and no longer recruiting.","summary":"Combination Immunotherapy in Rare Cancers Under InvesTigation is a phase 2 interventional study registered as NCT04969887 by Olivia Newton-John Cancer Research Institute, with a registry enrolment figure of 240 participants, started 2021-08-03 and due to reach its primary completion in 2025-03-01. Interventions recorded: Ipilimumab, Nivolumab. Conditions listed: Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor. Gallbladder cancer is named in the registry entry: \"* a) Histologically confirmed Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and Grade 3 NETs independent of primary site (SCLC excluded); Biliary Tract Cancers: Intrahepatic cholangiocarc\". Sites: Australia, New Zealand. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04969887","url":"https://clinicaltrials.gov/study/NCT04969887"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","intrahepatic-cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04969887-jama-oncol-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04969887","phase":"2","setting":"Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers","sponsor":"Olivia Newton-John Cancer Research Institute","enrolled":240,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04969887/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"paper":[{"id":"paper-nct04969887-jama-oncol-2025","kind":"paper","name":"Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial","route":"/key-papers/paper-nct04969887-jama-oncol-2025/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}